Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: YUSHIMA Study
International Journal of Urology · 2025-10 · 32 (10) · 1413-1418
DOI: 10.1111/iju.70154 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Urology, online erschienen am 16.06.2025. Verfasst von Yosuke Yasuda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Androgen Antagonists, Prostatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Androgen Receptor Antagonists. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
The phase 3 ARASENS and PEACE‐1 studies demonstrated significant survival benefits from triplet therapy (androgen deprivation therapy [ADT] plus androgen receptor signaling inhibitor plus docetaxel) versus ADT plus docetaxel alone. We examined the efficacy and safety of triplet therapy using the prospective observational clinical study: YUSHIMA study database.
Methods
We analyzed data on patients with metastatic hormone‐sensitive prostate cancer (mHSPC) treated with triplet therapy extracted from the YUSHIMA study database. Deep and early prostate‐specific antigen (PSA) response was defined as ≥ 90% PSA decline or PSA ≤ 0.2 ng/mL achievable at 3 months of treatment. Kaplan–Meier curves were used to assess overall survival (OS) and castration‐resistant prostate cancer (CRPC)–free survival. Adverse events (AEs) were graded using Common Terminology Criteria for Adverse Events version 5.0.
Results
Overall, 317 patients were enrolled in the YUSHIMA study from 2021 to 2025, of which 48 received triplet therapy. Organ metastases accounted for 25%. According to the CHAARTED and LATITUDE criteria, 77% and 73% of patients exhibited high‐volume and high‐risk disease, respectively. The 1‐year OS and CRPC‐free survival rates were 88% and 79%, respectively. Deep and early PSA response was achieved in 98%. In our cohort, grade 3–4 AEs appeared in 89% of cases, most of which were neutropenia. In 20% of cases, 6 courses of docetaxel could not be completed due to AEs.
Conclusions
Triplet therapy was highly efficacious and tolerable in Japanese mHSPC patients. Although most patients experienced grade 3–4 neutropenia, no cases were fatal. The deep and early PSA response represents a satisfactory short‐term result.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
- Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Urology, Japanese Red Cross Saitama Hospital, Saitama, Japan.
- Department of Urology, Saitama Cancer Center, Saitama, Japan.
- Department of Urology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
ORCID-Profile: Shunya Matsumoto, Hajime Tanaka, Ryoji Takazawa, Yoh Matsuoka, Yasuhisa Fujii
Zitieren
APA
Yasuda, Y., Numao, N., Matsumoto, S., Tamiya, T., Nakamura, Y., Tanaka, H., Yoshida, S., Kobayashi, S., Takazawa, R., Matsuoka, Y., Yonese, J., & Fujii, Y. (2025). Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: YUSHIMA Study. International Journal of Urology, 32(10), 1413-1418. https://doi.org/10.1111/iju.70154
Vancouver
Yasuda Y, Numao N, Matsumoto S, Tamiya T, Nakamura Y, Tanaka H, et al. Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: YUSHIMA Study. International Journal of Urology. 2025;32(10):1413-1418. doi:10.1111/iju.70154
BibTeX
@article{Yasuda2025,
author = {Yasuda, Yosuke and Numao, Noboru and Matsumoto, Shunya and Tamiya, Takashi and Nakamura, Yuki and Tanaka, Hajime and Yoshida, Soichiro and Kobayashi, Shuichiro and Takazawa, Ryoji and Matsuoka, Yoh and Yonese, Junji and Fujii, Yasuhisa},
title = {Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: YUSHIMA Study},
journal = {International Journal of Urology},
year = {2025},
volume = {32},
number = {10},
pages = {1413--1418},
doi = {10.1111/iju.70154}
}
EUVIMED